COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : La FDA accorde un examen prioritaire à la demande de licence de produits biologique relative à Dupixent® pour le traitement de la BPCO avec inflammation de type 2
23/02/2024
La FDA accorde un examen prioritaire à la demande de licence de produits biologique relative à Dupixent ® pour le traitement de la BPCO avec inflammation de type 2 Examen prioritaire accordé sur la base des résultats [...]
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23/02/2024
Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade [...]
Bionomics to Present at the 2024 BIO CEO & Investor Conference
22/02/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric [...]
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
22/02/2024
WARSAW, Ind., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
22/02/2024
ST. LOUIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients with a newly [...]
Healthcare Integrated Technologies, Inc. Announces Issuance of Second U.S. Patent for Innovative Transaction Validation System
22/02/2024
Knoxville, Tennessee, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions, is proud to announce the issuance of its second United [...]
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
22/02/2024
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full [...]
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
22/02/2024
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet [...]
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
22/02/2024
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Standard BioTools to Participate in Upcoming Investor Conferences
22/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that [...]
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
22/02/2024
SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year [...]
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22/02/2024
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024 On track to initiate first-in- [...]
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
22/02/2024
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets [...]
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
22/02/2024
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
22/02/2024
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life [...]
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
22/02/2024
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in [...]
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
22/02/2024
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
Health Catalyst Reports Fourth Quarter and Year End 2023 Results
22/02/2024
SOUTH JORDAN, Utah., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today [...]
Galapagos announces full year 2023 results and outlook for 2024
22/02/2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of [...]

Pages